BeyondSpring Shares Rise 2.4%

Biopharmaceutical company's stock price increases despite 'Sell' rating from analysts

Published on Feb. 20, 2026

Got story updates? Submit your updates here. ›

Shares of BeyondSpring Inc. (NASDAQ:BYSI), a clinical-stage biopharmaceutical company focused on developing cancer therapies, rose 2.4% during mid-day trading on Tuesday. The stock traded as high as $1.3399 before closing at $1.30, with approximately 13,361 shares traded, down from the average daily volume of 26,595 shares.

Why it matters

BeyondSpring's stock price increase comes despite a 'Sell' rating from analysts, highlighting potential investor interest in the company's pipeline of cancer treatments. The company's lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity, suggesting it could play a role in addressing key unmet needs in supportive care and tumor control.

The details

The stock's rise comes as BeyondSpring continues to advance its pipeline of cancer therapies. The company is a clinical-stage biopharmaceutical firm focused on discovering, developing, and commercializing novel small-molecule therapies for oncology. It is headquartered in Suzhou, China, with corporate operations in New York.

  • BeyondSpring's stock price rose 2.4% during mid-day trading on Tuesday, February 18, 2026.

The players

BeyondSpring Inc.

A clinical-stage biopharmaceutical company focused on developing cancer therapies, headquartered in Suzhou, China, with corporate operations in New York.

Geode Capital Management LLC

A hedge fund that recently raised its stake in BeyondSpring stock, now owning about 0.64% of the company's shares.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

BeyondSpring's stock price increase, despite a 'Sell' rating from analysts, suggests potential investor interest in the company's pipeline of cancer therapies, particularly its lead candidate plinabulin. The company's focus on developing novel small-molecule treatments for oncology could make it a company to watch in the biopharmaceutical space.